Email this article EVIDENCE-BASED USE OF EPLERENONE
- Authors: Gilyarevski S.R.1,2, Orlov V.A.3, Kuzmina I.M.1,2, Golshmid M.V.3, Zakharova G.Y.3, Sinitsina I.I.3
-
Affiliations:
- Sklifosovsky Institute of Emergency Surgery
- РМАПО
- Issue: Vol 6, No 1 (2012)
- Pages: 81-85
- Section: PHARMACOTHERAPY
- Published: 16.07.2014
- URL: https://klinitsist.abvpress.ru/Klin/article/view/75
- DOI: https://doi.org/10.17650/1818-8338-2012-1-81-85
- ID: 75
Cite item
Full Text
Abstract
Data of the negative effect of high concentrations of aldosterone in the blood for cardiovascular disease, which served as the theoretical basis for wider use in clinical practice of the drugs belonging to the class of aldosterone receptor blockers is presented. Evidence-based data on efficacy and safety of aldosterone receptor blockers, which were obtained in the course of several randomized clinical trials is performed. Particular attention is paid to aspects of the clinical use of selective aldosterone receptor blocker eplerenone, including current data, which makes reasonable extension of indications for its use in treating patients with chronic heart failure. Data on indications of eplerenone use in patients with hypertension, especially in the case of associated target organ damage is presented.
About the authors
S. R. Gilyarevski
Sklifosovsky Institute of Emergency Surgery;
Author for correspondence.
Email: sgilarevsky@rambler.ru
Russian Federation
V. A. Orlov
РМАПОDepartment of Clinical Pharmacology and Therapeutics Russian Federation
I. M. Kuzmina
Sklifosovsky Institute of Emergency Surgery;Russian Federation
M. V. Golshmid
РМАПОDepartment of Clinical Pharmacology and Therapeutics Russian Federation
G. Y. Zakharova
РМАПОDepartment of Clinical Pharmacology and Therapeutics Russian Federation
I. I. Sinitsina
РМАПОDepartment of Clinical Pharmacology and Therapeutics Russian Federation
References
Supplementary files
